Sellas Life Sciences Group Inc (SLS)

Jan 18, 2025

SELLAS Life Sciences amends executive severance agreements - MSN

Jan 18, 2025

Jan 18, 2025

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS) - Defense World

Jan 18, 2025

Jan 17, 2025

SELLAS Life Sciences Group Inc (NASDAQ: SLS): Blank Check On Growth? - Stocks Register

Jan 17, 2025

Jan 17, 2025

SELLAS Life Sciences Group Approves Amendments to Change in Control Severance Agreements - Defense World

Jan 17, 2025

Jan 16, 2025

SELLAS Life Sciences amends executive severance agreements By Investing.com - Investing.com Nigeria

Jan 16, 2025

Jan 16, 2025

SELLAS Life Sciences Amends Severance for Key Executives - TipRanks

Jan 16, 2025

Jan 14, 2025

Analyze SELLAS Life Sciences Group Inc (NASDAQ: SLS) Before Investing. - Stocks Register

Jan 14, 2025

Jan 11, 2025

Geode Capital Management LLC Has $757,000 Position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World

Jan 11, 2025

Jan 08, 2025

SELLAS advances cancer drug trials, eyes key 2025 milestones - Investing.com

Jan 08, 2025

Jan 08, 2025

SELLAS Announces Key Business Objectives for 2025 - GlobeNewswire

Jan 08, 2025

Jan 08, 2025

SELLAS Life Sciences' Cancer Drug Shows 3x Better Survival Rate in Advanced Leukemia Study - StockTitan

Jan 08, 2025

Jan 04, 2025

State Street Corp Increases Stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World

Jan 04, 2025

Jan 02, 2025

SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET - GlobeNewswire

Jan 02, 2025

Jan 02, 2025

SELLAS Life Sciences Announces 2025 Corporate Strategy Call with CEO and Cancer Expert - StockTitan

Jan 02, 2025

Dec 29, 2024

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Down 17.6% in December - MarketBeat

Dec 29, 2024

Dec 22, 2024

62,785 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Acquired by XTX Topco Ltd - Defense World

Dec 22, 2024

Dec 18, 2024

United Rentals (URI-N) QuotePress Release - The Globe and Mail

Dec 18, 2024

Dec 11, 2024

SELLAS Life Sciences Group, Inc. Triggers Interim Analysis in Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia - Marketscreener.com

Dec 11, 2024

Dec 10, 2024

SELLAS Life Sciences Advances Phase 3 AML Trial - TipRanks

Dec 10, 2024

Dec 10, 2024

SELLAS triggers interim analysis in AML trial - Investing.com

Dec 10, 2024

Dec 10, 2024

SELLAS triggers interim analysis in AML trial By Investing.com - Investing.com Canada

Dec 10, 2024

Dec 10, 2024

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia - GlobeNewswire

Dec 10, 2024

Dec 10, 2024

SELLAS Life Sciences Hits Major Milestone in Phase 3 AML Cancer Treatment Trial - StockTitan

Dec 10, 2024

Dec 10, 2024

SELLAS reports promising AML drug trial results By Investing.com - Investing.com Canada

Dec 10, 2024

Dec 09, 2024

SELLAS reports promising AML drug trial results - Investing.com India

Dec 09, 2024

Dec 09, 2024

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML - The Manila Times

Dec 09, 2024

Dec 09, 2024

SELLAS Announces Positive Overall Survival and Overall - GlobeNewswire

Dec 09, 2024

Dec 09, 2024

SELLAS' SLS009 Triples Survival Time in Phase 2 AML Trial, Shows Breakthrough Response Rates - StockTitan

Dec 09, 2024

Dec 08, 2024

Anson Funds Management LP Purchases Shares of 793,835 SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - MarketBeat

Dec 08, 2024

Nov 28, 2024

SELLAS announces data indicating key predictor of response to SLS009 in solid cancers - Yahoo Finance

Nov 28, 2024

Nov 27, 2024

SELLAS Announces Positive Data from Preclinical Studies - GlobeNewswire

Nov 27, 2024

Nov 27, 2024

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor - The Bakersfield Californian

Nov 27, 2024

Nov 27, 2024

SELLAS Life Sciences' SLS009 Shows 67% Efficacy in ASXL1-Mutated Cancer Study | SLS Stock News - StockTitan

Nov 27, 2024

Nov 23, 2024

Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely - Simply Wall St

Nov 23, 2024

Nov 16, 2024

We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate - Yahoo Finance

Nov 16, 2024

Nov 15, 2024

S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail

Nov 15, 2024

Nov 13, 2024

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 13, 2024

Nov 13, 2024

SELLAS Reports 31% Response Rate in AML Trial, Narrows Q3 Loss to $7.1M | SLS Stock News - StockTitan

Nov 13, 2024

Nov 08, 2024

Highbridge Capital Management's Strategic Acquisition of SELLAS Life Sciences Shares - GuruFocus.com

Nov 08, 2024

Nov 05, 2024

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024 - GlobeNewswire

Nov 05, 2024

Nov 05, 2024

Northrop Grumman Corp (NOC-N) QuotePress Release - The Globe and Mail

Nov 05, 2024

Nov 05, 2024

SELLAS' Cancer Drug Shows 50% Response Rate in Leukemia Trial, Doubles Survival Time | SLS Stock News - StockTitan

Nov 05, 2024

Oct 27, 2024

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Decrease in Short Interest - MarketBeat

Oct 27, 2024

Oct 23, 2024

Galinpepimut-S Gets Rare Pediatric Disease Designation for AML - Hematology Advisor

Oct 23, 2024

Oct 15, 2024

FDA grants rare pediatric disease designation to SELLAS cancer drug By Investing.com - Investing.com Australia

Oct 15, 2024

Oct 15, 2024

SELLAS Announces U.S. FDA Rare Pediatric Disease - GlobeNewswire

Oct 15, 2024

Oct 15, 2024

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S - The Bakersfield Californian

Oct 15, 2024

Oct 15, 2024

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia - StockTitan

Oct 15, 2024

Oct 10, 2024

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - GlobeNewswire

Oct 10, 2024

Oct 10, 2024

Trading Day Triumph: SELLAS Life Sciences Group Inc (SLS) Ends at 1.19, a -2.46 Surge/Plunge - The Dwinnex

Oct 10, 2024

Oct 08, 2024

Nvidia Corp (NVDA-Q) QuotePress Release - The Globe and Mail

Oct 08, 2024